Article Text

Download PDFPDF

AB0096 Efficacy and safety of oral administration of pure celastrol in aia rats
  1. R Cascão1,
  2. T Carvalho1,
  3. J Goncalves2,
  4. LF Moita3,
  5. JE Fonseca4
  1. 1Instituto de Medicina Molecular
  2. 2iMed – Research Institute of Medicines, Faculdade de Farmácia, Universidade de Lisboa, Lisbon
  3. 3Instituto Gulbenkian de Ciência, Oeiras
  4. 4Instituto de Medicina Molecular and Rheumatology Department, Centro Hospitalar de Lisboa Norte, EPE, Hospital de Santa Maria, Lisbon Academic Medical Centre, Lisbon, Portugal


Background Celastrol, a pentacyclic-triterpene isolated from Tripterigium wilfordii roots, has shown great therapeutic potential for the treatment of several inflammatory diseases, including rheumatoid arthritis (RA). We have previously demonstrated that celastrol has significant anti-inflammatory and bone protective effects in the adjuvant-induced rat model of arthritis (AIA), when administered via intraperitoneal route. For further preclinical evaluation of celastrol as a candidate compound for RA treatment, an effective and safe oral administration is crucial.

Objectives In this work we aimed to study the dose range for both therapeutic and toxic effects for oral administration of pure celastrol using the AIA rat model.

Methods Celastrol (1, 2.5, 5, 7.5, 12.5 and 25μg/g/day, N=5/group) was administrated orally in female AIA rats after 8 days of disease induction (therapeutic model) for a period of 14-days. A group of healthy (N=8) and untreated arthritic (vehicle, N=15) gender and age-matched Wistar rats were used as control. During the period of treatment, the inflammatory score, ankle perimeter and body weight were measured. At the end of the treatment, animals were sacrificed, blood was collected for clinical pathology, and necropsy was performed, with collection of internal organs for histopathological analysis and of paw samples for disease scoring.

Results Oral administration of pure celastrol at 2.5, 5 and 7.5μ g/g/day reduced the inflammatory score and ankle swelling, preserved articular joint structure with a reduction in synovial inflammatory infiltrates and proliferation, halted articular bone destruction, and diminished the number of synovial CD68+ macrophages (a biomarker of response to anti-arthritic treatment). This compound also reduced the number of osteoclasts and osteoblasts present in joints. Bone resorption and turnover was also reduced at both 5 and 7.5μg/g/day, with a significant decrease in serum levels of TRACP-5b, P1NP and CTX-I. Of note, no significant variation in body weight, evidence of nephro-, hepato- or cardiotoxic effects, nor alterations in blood cell counts were observed at these concentrations. However, the dose of 7.5μ g/g/day was already associated with thymic and hepatotoxic changes, and higher doses showed toxicity signs. The lethal dose (LD) and LD50 were defined as 25μg/g/day and 12.5μg/g/day, respectively. Of note, oral celastrol at 1μg/g/day had no effect in arthritis progression.

Conclusions Our results clearly show that 2.5μg/g/day is the lowest and 5μg/g/day is the highest effective and safe oral doses of celastrol in the setting of AIA rat model. These findings suggest that while celastrol is potentially very effective to treat RA, it has a narrow therapeutic window.

Acknowledgements The authors would like to acknowledge Bruno Vidal and Inês Lopes for technical assistance.

Disclosure of Interest None declared

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.